Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Medicinas Complementares
Métodos Terapêuticos e Terapias MTCI
Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Thromb Res ; 98(4): 333-42, 2000 May 15.
Artigo em Inglês | MEDLINE | ID: mdl-10822080

RESUMO

When activated in vitro, thrombin-activatable fibrinolysis inhibitor (TAFI) slows clot lysis by cleaving the C-terminal lysine and arginine residues from partially degraded fibrin. An inhibitor of carboxypeptidase isolated from potato (CPI) reverses prolongation of clot lysis by inhibiting activated TAFI. We investigated in vivo effect of TAFI inhibition on tissue-type plasminogen activator (t-PA)-induced clot lysis using CPI in a rabbit jugular vein thrombolysis model. It was found necessary to further purify the CPI preparations from commercial sources by HPLC chromatography to remove endotoxin and anti-plasmin activity that would affect the endogenous fibrinolytic system. The effect of intravenous administration of the purified CPI with t-PA was determined by measuring thrombus weight at the end of 90 minutes in six groups of animals. In the control group receiving saline, the median thrombus weight was 116 mg. In the group that received CPI only (0.5 mg/kg bolus injection followed by 0.3 mg/kg/h infusion), the median thrombus weight was 121 mg. In the group that received t-PA at a dose of 10 microg/kg bolus followed by 67 microg/kg/h infusion, the median thrombus weight decreased to 86 mg. When CPI was coadministered with the same regimen of t-PA, the median value further decreased to 58 mg. When animals were given three times higher the dose of t-PA (30 microg/kg bolus followed by 200 microg/kg/h infusion) in the absence or presence of CPI, median thrombus weights were 56 mg and 0 mg, respectively. Our results demonstrate that systemic coadministration of the purified CPI improves clot lysis induced by t-PA.


Assuntos
Carboxipeptidases/antagonistas & inibidores , Fibrina/metabolismo , Fibrinólise/efeitos dos fármacos , Proteínas de Plantas/uso terapêutico , Trombina/fisiologia , Terapia Trombolítica , Ativador de Plasminogênio Tecidual/uso terapêutico , Trombose Venosa/tratamento farmacológico , Animais , Carboxipeptidase B2 , Carboxipeptidases/fisiologia , Cromatografia Líquida de Alta Pressão , Avaliação Pré-Clínica de Medicamentos , Sinergismo Farmacológico , Endotélio Vascular/fisiopatologia , Ativação Enzimática/efeitos dos fármacos , Fibrinogênio/metabolismo , Infusões Intravenosas , Proteínas de Plantas/administração & dosagem , Proteínas de Plantas/isolamento & purificação , Proteínas de Plantas/farmacologia , Plasminogênio/metabolismo , Inibidores de Proteases , Coelhos , Solanum tuberosum/enzimologia , Ativador de Plasminogênio Tecidual/farmacologia , alfa 2-Antiplasmina/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA